prof. david brayden, ucd
TRANSCRIPT
Academic-Industrial Collaborations: The SFI Irish Drug Delivery Network Cluster (IDDN)
David Brayden, Ph.D
Global Biopharm Summit, October 31st, 2012
www.ucd.ie/iddn
IDDN skills
TCDTCD
RCSIRCSI
UCDUCD
UCCUCC
Industry partners
Processing Improvements
Aeroneb™ nebulisers for pulmonary delivery
Peptide to prevent bleeding in laproscopic surgery
Liquid Emulsion DDS ™ for oral peptides
Example 1: Sigmoid’s LEDDS™: Liquid Emulsion Drug Delivery System
● API is solubilised as an emulsion, microemulsion or suspension
●Formulated into mini-spheres
●Coated by conventional or novel technologies
IDDN’s oral delivery bioassays
Regional Instillation
Single pass perfusion
Oral gavage
Caco-2 Ussing chamber
Making a colonic LEDDS ™ calcitonin
AAPS Biotech, 2012. T. Aguirre et al
Example 2: Aerogen’s device
High Speed Microscopic Photo of Uniform Aerosol
Droplets Generated from a Single Aperture
High quality aerosol
Stability of proteins post-nebulisation using Aeroneb®
RP-HPLC of calcitonin pre- and post nebulisation
SEC of calcitonin pre- and post-nebulisationS. Cryan, R. MacLoughlin
Example 3: An unanticipated ‘nano’ discovery…
L. Tajber, A. UmerskaS. Ryan, E. Murphy
1 2 3 4 540
60
80
100
Day%
Red
uctio
n in
kn
ee d
iam
eter
***
***
Saline control Nanoparticle
The ‘nano’ resolves inflammation in K/BxN mouse
NPSteroidsCTSaline
Int. Patent Appl. WO 2012/052565A1
SFI Travel Fellowship
Lipophilic groups
Cationic groups
β-cyclodextrin
‘Click’ linker
siRNA
Example 4: Cyclovector™ for siRNA delivery
R. Darcy, M. Devocelle, C’O’Driscoll
▫ Widely used model, aberrant human HD gene. Early onset (12-14weeks)
▫ Mutant gene knock-down by CD-siRNA (HTT) by qPCR from spinal cord
Mouse R6/2 model of HD
CON TESTJohn Cryan, Bruno Godino, Caitriona O’Driscoll (UCC)
R6/2 mice: behavioural studies
B. Godhino, C. O’Driscoll
IDDN outputs (2008-2012)
5 Patent Applications
Bespoke modular
programs for industry
9 Books /Technical
reports
93 papers and reviews
68 conference proceedings
5 Invention Disclosures
8 PhDs and 1 MSc Awarded
101 International Presentations
70 National Presentations
EU funding National groups Pharma
“TRANS-INT” FP7: NMP.2011.1.2-2: New targeted therapy using nanotechnology for transport of macro-molecules across biological barriers
• FP7 worth €8.2m over 5 years• 3 Irish partners from IDDN• Oral nanocarriers designed for peptides will be tested in a systematic
way across specialist labs• Peptide cargoes: recombinant insulin, two others not in public domain
Centre for Biomaterials and Biodelivery• Pools complimentary skill sets of two successful SFI Clusters with
UCD Nanomedicine Centre• Creation of “Centre of Excellence” for integration delivery with
biomaterials and medical devices• Bid contains pledges of support from Irish Industry to a value of
€5 Million in priority research areas
Delivery research needs…..
• Providing supporting research data for programme
• New research that cannot be done in-house
• Bespoke taught modules (CPD)• Industry staff registered in
postgraduate research programmes
21
Benefits to industry partners?
Learnings…• Industry interacted with academics through single mechanism• Innovative drug delivery from start-ups, SMEs, other academics• Hooking up with SFI Biomaterials cluster has opened up
medical device opportunities• Having a Cluster provided visibility via EI and IDA • Cluster structure positioned team for FP7 bid
